Autologus regenerative skin cell therapy - Regenicin

Drug Profile

Autologus regenerative skin cell therapy - Regenicin

Alternative Names: NovaDerm; NovaDerm™ skin substitute

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator Regenicin
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Burns

Most Recent Events

  • 01 Nov 2016 Regenicin completes pre-IND meeting with the US FDA for Autologous regenerative skin cell therapy
  • 29 Aug 2016 Autologus regenerative skin cell therapy - Regenicin receives Orphan Drug status for Burns in USA
  • 12 Feb 2016 Regenicin enters into an agreement with an undisclosed institution to co-develop for scientific information for NovaDerm™ in USA for Burns
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top